Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 41.52 Million USD | -90.52% |
| 2022 | 437.96 Million USD | 4.14% |
| 2021 | 420.55 Million USD | 7.74% |
| 2020 | 390.33 Million USD | 3.92% |
| 2019 | 375.61 Million USD | 14.01% |
| 2018 | 329.46 Million USD | 1141.33% |
| 2017 | 26.54 Million USD | 537.24% |
| 2016 | 4.16 Million USD | -42.06% |
| 2015 | 7.18 Million USD | -73.32% |
| 2014 | 26.94 Million USD | -21.65% |
| 2013 | 34.39 Million USD | 50.21% |
| 2012 | 22.89 Million USD | -22.35% |
| 2011 | 29.48 Million USD | -60.69% |
| 2010 | 75 Million USD | 0.0% |
| 2009 | 75 Million USD | 0.0% |
| 2008 | 75 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 42.12 Million USD | 1.44% |
| 2024 Q3 | 28.92 Million USD | -4.56% |
| 2024 Q2 | 39.97 Million USD | -5.1% |
| 2023 FY | 41.52 Million USD | -90.52% |
| 2023 Q1 | 517.37 Million USD | 18.13% |
| 2023 Q3 | 42.32 Million USD | 0.3% |
| 2023 Q2 | 42.19 Million USD | -91.84% |
| 2023 Q4 | 41.52 Million USD | -1.88% |
| 2022 Q3 | 437.46 Million USD | -1.7% |
| 2022 FY | 437.96 Million USD | 4.14% |
| 2022 Q1 | 446.41 Million USD | 6.15% |
| 2022 Q2 | 445.02 Million USD | -0.31% |
| 2022 Q4 | 437.96 Million USD | 0.11% |
| 2021 FY | 420.55 Million USD | 7.74% |
| 2021 Q3 | 412.04 Million USD | 1.36% |
| 2021 Q2 | 406.52 Million USD | 3.03% |
| 2021 Q1 | 394.57 Million USD | 1.09% |
| 2021 Q4 | 420.55 Million USD | 2.06% |
| 2020 Q3 | 413.68 Million USD | 1.0% |
| 2020 FY | 390.33 Million USD | 3.92% |
| 2020 Q1 | 380.03 Million USD | 1.18% |
| 2020 Q2 | 409.6 Million USD | 7.78% |
| 2020 Q4 | 390.33 Million USD | -5.65% |
| 2019 Q2 | 364.74 Million USD | 1.0% |
| 2019 Q1 | 361.13 Million USD | 9.61% |
| 2019 Q3 | 368.41 Million USD | 1.01% |
| 2019 FY | 375.61 Million USD | 14.01% |
| 2019 Q4 | 375.61 Million USD | 1.95% |
| 2018 Q4 | 329.46 Million USD | 1.17% |
| 2018 Q3 | 325.66 Million USD | 1.16% |
| 2018 FY | 329.46 Million USD | 1141.33% |
| 2018 Q2 | 321.92 Million USD | 1.16% |
| 2018 Q1 | 318.22 Million USD | 1098.99% |
| 2017 Q4 | 26.54 Million USD | -5.06% |
| 2017 Q3 | 27.95 Million USD | 1799.18% |
| 2017 Q2 | 1.47 Million USD | -55.53% |
| 2017 Q1 | 3.31 Million USD | -20.53% |
| 2017 FY | 26.54 Million USD | 537.24% |
| 2016 FY | 4.16 Million USD | -42.06% |
| 2016 Q1 | 5.62 Million USD | -21.73% |
| 2016 Q3 | 5.77 Million USD | 1.28% |
| 2016 Q4 | 4.16 Million USD | -27.84% |
| 2016 Q2 | 5.69 Million USD | 1.28% |
| 2015 Q1 | 11.7 Million USD | -56.55% |
| 2015 FY | 7.18 Million USD | -73.32% |
| 2015 Q4 | 7.18 Million USD | -10.89% |
| 2015 Q3 | 8.06 Million USD | -7.92% |
| 2015 Q2 | 8.76 Million USD | -25.16% |
| 2014 Q1 | 28.35 Million USD | -17.55% |
| 2014 FY | 26.94 Million USD | -21.65% |
| 2014 Q4 | 26.94 Million USD | 1.7% |
| 2014 Q3 | 26.49 Million USD | -7.58% |
| 2014 Q2 | 28.67 Million USD | 1.1% |
| 2013 Q3 | 60.17 Million USD | 1.82% |
| 2013 Q4 | 34.39 Million USD | -42.85% |
| 2013 Q1 | 20.11 Million USD | -12.16% |
| 2013 FY | 34.39 Million USD | 50.21% |
| 2013 Q2 | 59.1 Million USD | 193.85% |
| 2012 Q2 | 27.8 Million USD | -4.43% |
| 2012 Q3 | 25.6 Million USD | -7.92% |
| 2012 Q4 | 22.89 Million USD | -10.58% |
| 2012 FY | 22.89 Million USD | -22.35% |
| 2012 Q1 | 29.09 Million USD | -1.32% |
| 2011 FY | 29.48 Million USD | -60.69% |
| 2011 Q3 | 89.51 Million USD | 0.0% |
| 2011 Q4 | 29.48 Million USD | -67.06% |
| 2010 FY | 75 Million USD | 0.0% |
| 2010 Q4 | 75 Million USD | 0.0% |
| 2010 Q3 | 75 Million USD | 0.0% |
| 2009 FY | 75 Million USD | 0.0% |
| 2009 Q4 | 75 Million USD | 0.0% |
| 2008 FY | 75 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | 29.577% |
| Harrow Health, Inc. | 190.5 Million USD | 78.201% |
| Dynavax Technologies Corporation | 256.91 Million USD | 83.836% |
| Biofrontera Inc. | 5.39 Million USD | -669.161% |
| Cronos Group Inc. | 2.53 Million USD | -1534.961% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -6730.099% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 94.196% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -14.327% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -3440.221% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -125.341% |
| Radius Health, Inc. | 365.31 Million USD | 88.632% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -657.452% |
| DURECT Corporation | 20.74 Million USD | -100.169% |
| ProPhase Labs, Inc. | 21.38 Million USD | -94.233% |
| Safety Shot Inc | 1.54 Million USD | -2580.936% |
| Phibro Animal Health Corporation | 525.45 Million USD | 92.097% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -1468.563% |
| Alvotech | 1.07 Billion USD | 96.139% |
| Assertio Holdings, Inc. | 40.91 Million USD | -1.503% |
| Rockwell Medical, Inc. | 13.43 Million USD | -209.004% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -6213.925% |
| Procaps Group S.A. | 285.93 Million USD | 85.477% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -145.171% |
| SCYNEXIS, Inc. | 15.08 Million USD | -175.378% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -174.486% |
| Viatris Inc. | 18.12 Billion USD | 99.771% |
| OptiNose, Inc. | 131.74 Million USD | 68.48% |
| SIGA Technologies, Inc. | 1.46 Million USD | -2736.526% |
| Tilray Brands, Inc. | 387.31 Million USD | 89.278% |
| PetIQ, Inc. | 468.3 Million USD | 91.132% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -6213.925% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 90.306% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | 38.386% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 93.841% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -3717.894% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 65.206% |
| Journey Medical Corporation | 17.73 Million USD | -134.219% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -401.74% |
| Alpha Teknova, Inc. | 30.45 Million USD | -36.342% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -1889.794% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 68.144% |
| PainReform Ltd. | 86 Thousand USD | -48187.209% |
| Cosmos Health Inc. | 12.42 Million USD | -234.25% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -17.361% |
| TherapeuticsMD, Inc. | 8 Million USD | -418.763% |
| Embecta Corp. | 1.63 Billion USD | 97.466% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -69335.016% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 92.914% |
| Incannex Healthcare Limited | 373 Thousand USD | -11033.244% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -3919.591% |
| Shineco, Inc. | 29.65 Million USD | -40.027% |
| Procaps Group, S.A. | 285.93 Million USD | 85.477% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 86.831% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 57.978% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 93.269% |
| Alvotech | 1.07 Billion USD | 96.139% |
| Hempacco Co., Inc. | 13.72 Million USD | -202.576% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 33.521% |
| Bright Green Corporation | 1.85 Million USD | -2142.541% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 92.323% |
| Kamada Ltd. | 8.74 Million USD | -374.649% |
| Indivior PLC | 281.6 Million USD | 85.253% |
| Evoke Pharma, Inc. | 5 Million USD | -730.54% |
| Flora Growth Corp. | 3.67 Million USD | -1030.91% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -3919.591% |
| Evolus, Inc. | 126.54 Million USD | 67.184% |
| HUTCHMED (China) Limited | 86.13 Million USD | 51.786% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 93.341% |
| Akanda Corp. | 3.99 Million USD | -938.489% |